The debt refinancing extends maturities and addresses near-term maturities (Dec 2026 and Feb 2027). Monitor the concurrent euro note offering for completion and total combined proceeds. Watch for any use of proceeds toward share repurchases or M&A, which could signal capital allocation priorities.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $107.32entry
- T+1 · 6d ago +0.14%α −1.18% · $107.47
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zimmer Biomet is issuing $500M of 5.850% senior notes due 2036 in an underwritten debt offering, with net proceeds of ~$495.1M to be used for general corporate purposes including potential repayment of near-term maturities (€500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027), share repurchases, and acquisitions. The offering follows a Q3 earnings report that showed modest revenue growth and raised guidance, and is concurrent with a separate €500M euro note offering.
Key Financial Metrics
Key Facts
- $500,000,000 aggregate principal amount of 5.850% notes due 2036
- Net proceeds estimated at ~$495.1 million after underwriting discount and expenses
- Notes are unsecured, unsubordinated obligations ranking equally with existing unsecured debt
- Proceeds may be used to repay portions of €500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027
- Concurrent €500M offering of 4.375% notes due 2033 is not contingent on this offering
- Underwriting discount of 0.650% ($3.25M total); 18 underwriters led by Barclays, BofA, J.P. Morgan, Mizuho, SMBC Nikko
- Certain underwriters may receive ≥5% of proceeds due to potential debt repayment, triggering FINRA Rule 5121 conflict of interest disclosure
- Filed 5 days after Q3 2026 earnings (Nov 4) which showed +3.1% revenue growth and raised full-year guidance
Financial Impact
$500M debt issuance; net proceeds ~$495.1M; existing consolidated debt ~$7.5B as of Sep 30, 2026
Risk Factors
- Notes are structurally subordinated to subsidiary liabilities; no restriction on additional unsecured debt
- Change of control repurchase event (101% of principal) triggered only if both change of control and below-investment-grade rating event occur
- No established trading market for the notes; liquidity risk for holders
- Interest rate increases could reduce market value of fixed-rate notes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-453600 |
| Document: d84533dexfilingfees.htm | 0001193125-26-453600 |
| Document: 0001193125-26-453600-index-headers.html | 0001193125-26-453600 |
| Document: 0001193125-26-453600-index.html | 0001193125-26-453600 |
| Document: 0001193125-26-453600.txt | 0001193125-26-453600 |
Track record
17 reports on ZBH
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.74% at T+60 after the Apr 28, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $103.21 Now $101.41 −1.74% settles Nov 20
- Nov 9, 20267d ago 424B5 Neutral 3/10 Viewing Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 5, 202611d ago 424B5 Neutral 2/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
- Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
- Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
- Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
- Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers